BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15570930)

  • 1. [Infection control in neutropenia induced by high-dose cytarabine chemotherapy].
    Miyazaki M; Senzaki K; Kiyoi H; Kohno S; Noda Y; Nabeshima T
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2011-5. PubMed ID: 15570930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
    Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
    Kawasaki Y; Kimura SI; Nakano H; Mashima K; Shirato Y; Kawaguchi SI; Toda Y; Ochi SI; Nagayama T; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Fujiwara SI; Ohmine K; Kako S; Muroi K; Kanda Y
    Int J Hematol; 2019 Apr; 109(4):470-476. PubMed ID: 30684252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
    Lech-Maranda E; Seweryn M; Giebel S; Holowiecki J; Piatkowska-Jakubas B; Wegrzyn J; Skotnicki A; Kielbinski M; Kuliczkowski K; Paluszewska M; Jedrzejczak WW; Dutka M; Hellmann A; Flont M; Zdziarska B; Palynyczko G; Konopka L; Szpila T; Gawronski K; Sulek K; Sokolowski J; Kloczko J; Warzocha K; Robak T
    Int J Infect Dis; 2010 Feb; 14(2):e132-40. PubMed ID: 19581118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
    Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR
    Am J Hematol; 2007 Dec; 82(12):1056-62. PubMed ID: 17696203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Piciocchi A; Del Principe MI; Sarlo C; Di Veroli A; Panetta P; Irno-Consalvo M; Nasso D; Ditto C; Refrigeri M; De Angelis G; Cerretti R; Arcese W; Sconocchia G; Lo-Coco F; Amadori S; Venditti A
    Am J Hematol; 2015 Feb; 90(2):125-31. PubMed ID: 25377359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia].
    López A; Soler JA; Juliá A; Novo A; Bueno J
    Med Clin (Barc); 1994 Jan; 102(3):81-5. PubMed ID: 8133717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
    Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
    Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
    Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
    Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
    Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A
    Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine.
    Johannsen KH; Handrup MM; Lausen B; Schrøder H; Hasle H
    Pediatr Blood Cancer; 2013 Jul; 60(7):1154-60. PubMed ID: 23281248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols.
    Yilmaz S; Oren H; Demircioğlu F; Irken G
    Pediatr Hematol Oncol; 2008; 25(3):195-204. PubMed ID: 18432502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloprotective effect of short-course high-dose methylprednisolone treatment before consolidation therapy in children with acute myeloblastic leukemia.
    Elmas SA; Cetin M; Tuncer M; Hiçsönmez G
    Am J Hematol; 2005 Sep; 80(1):1-5. PubMed ID: 16138333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of chemotherapy courses on the rate of bloodstream infections during neutropenia in adult acute myeloid leukaemia.
    Kinnunen U; Koistinen P; Ohtonen P; Koskela M; Syrjälä H
    Scand J Infect Dis; 2008; 40(8):642-7. PubMed ID: 18979602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.